Beckley Psytech, a psychedelic medicine company with deep ties to the historical Beckley Foundation, has raised £14m of new equity funding to develop psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

We are very excited to announce that Joanna Neill, Professor of Psychopharmacology at the University of Manchester, and Dr Mike Emanuel, former vice president of global clinical operations for EMEA at Johnson & Johnson, are joining our Scientific Advisory Board. As a members of our Board, they will be in esteemed company alongside some of the world’s leading psychedelic and psychiatric researchers, and drug development specialists. Read on to learn about the experience and expertise both Joanna and Mike will bring to our business below.

Renowned experts bring decades of experience to Beckley Psytech

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Beckley Psytech today announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC) investors to fund its promising research programmes.

Dr. Laura Trespidi joins leadership team as Chief Development Officer

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trialsNew digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s)Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team

OXFORD, England (BUSINESS WIRE) Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress, taking place in London from 10th to 11th May 2022, and will hold a formal presentation in front of investors.

OXFORD, England — Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 32nd Annual Oppenheimer Healthcare Conference, taking place virtually from March 15th to 17th, 2022 and will hold a formal presentation in front of investors.